Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Premier Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$658,020

155 payments

Through program year 2025, Premier Clinical Research LLC is reported as receiving $658,020 in research payments, across 155 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $149,320 22
2024 Research $102,079 28
2023 Research $105,133 23
2022 Research $147,094 31
2021 Research $75,199 6
2020 Research $52,508 27
2019 Research $26,687 18

Breakdown

Who paid Research payments · program years 2019–2025
  1. Janssen Research & Development, LLC $174,481 42 payments
  2. Vanda Pharmaceuticals Inc. $140,623 39 payments
  3. Amgen Inc. $89,257 2 payments
  4. AbbVie, Inc. $83,033 29 payments
  5. Merz North America, Inc. $55,490 5 payments
  6. Horizon Therapeutics plc $27,667 2 payments
  7. Genentech, Inc. $23,977 5 payments
  8. Otsuka Pharmaceutical Development & Commercialization, Inc. $23,714 1 payment
  9. Neurocrine Biosciences, Inc. $18,087 16 payments
  10. VYNE Pharmaceuticals Inc. $13,090 12 payments
Studies the money was for Research payments · program years 2019–2025
  1. An Open Label Study to Investigate the Safety and Efficacy of Tradipitant in Participants Affected By Motion Sickness $89,700 19 payments
  2. A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity $89,257 2 payments
  3. A Phase 2a Multi Center Randomized Double blind Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab and Golimumab Combination Therapy in Participants with Active Psoriatic Arthritis $77,525 18 payments
  4. Evaluation of the Octave Platform for the Ulthera System for Improving Laxity and Wrinkles on the Decollete $55,490 5 payments
  5. A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) $50,956 17 payments
  6. Evaluating the Effects of Tradipitant Vs. Placebo in Atopic Dermatitis $42,723 17 payments
  7. Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent $41,036 12 payments
  8. A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease $29,893 8 payments
  9. A Multi Center Randomized Double blind Parallel group Placebo controlled Proof of concept Study Evaluating the Efficacy and Safety of Nipocalimab Administered Intravenously in Participants with Active Rheumatoid Arthritis Despite Standard Therapy $26,027 4 payments
  10. Randomised Double Blind Study to Evaluate Safety and Efficacy of Obinutuzumab in Class III and IV LN $23,977 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record